When Direct Compression Replaces Wet Massing in Low-Dose Veterinary Tablet Cores

Diphenoxylate hydrochloride for companion-animal antidiarrheal tablet cores is normally introduced at a nominal content of 2.5 mg per unit with 0.025 mg atropine sulfate as the fixed-dose deterrent component. In a 250 mg direct-compression core, the API is present at 1.0% w/w and atropine sulfate at 0.01% w/w, so the controlling variable is not dissolution rate but segregative loss of the low-mass active during transfer and press feed. Raw API should not be added directly to the final excipient blend. A staged pre-blend is prepared at 1:10 diphenoxylate HCl-to-lactose monohydrate ratio through a 500 µm stainless-steel screen, then diluted again at 1:10 with microcrystalline cellulose before entering a V-blender or bin blender. Final blend samples are pulled from 10 locations after blending; compressed units are tested under USP <905> and must meet an acceptance value ≤ 15.0. If ambient relative humidity exceeds 60%, lactose monohydrate is pre-dried at 40°C for 2 h before blending, because pick-up on rotary press punches and die-table dusting are the primary compaction failures. Compression is conducted on a rotary tablet press with force feeders; core hardness is maintained between 40 N and 80 N, friability ≤ 1.0% by Ph. Eur. 2.9.7, and disintegration ≤ 15 min by Ph. Eur. 2.9.1. Compliance for veterinary use is anchored to 21 CFR Part 530 for extralabel administration in companion animals where no approved veterinary product exists, with residual solvents under VICH GL18 and elemental impurities under ICH Q3D. Terminal product type is a round biconvex antidiarrheal tablet in PVC/PVDC/Alu blister or HDPE bottle with desiccant, labelled for prescription use in dogs with acute nonspecific diarrhoea and explicitly excluding food-producing species.

Why Does Low-Dose Capsule Filling Fail Without Geometric Dilution Before Encapsulation?

Capsule presentation for veterinary hospital dispensing is prepared by non-sterile compounding rather than licensed pharmaceutical manufacture, and the principal defect is content non-uniformity caused by dry powder stratification. A working blend is built in two steps: 1:9 diphenoxylate HCl-to-lactose monohydrate trituration followed by a second 1:9 dilution to a final concentration of 1.0% w/w. Direct weighing of undiluted API into individual capsules is not acceptable for low-dose units; the minimum weighable mass must remain above the balance’s acceptable repeatability threshold, typically 10 mg for an analytical balance with 0.1 mg readability. Semi-automatic capsule equipment with tamping pins shows acceptable fill-weight variation below ±5% only when powder bed bulk density is maintained between 0.55 g/mL and 0.65 g/mL; a lower bulk density produces underweight top segments and a higher tapped density causes over-compression of the powder slug. Compliance is set by USP <795> for non-sterile compounding and USP <800> where the facility classifies the API as a hazardous drug; without site-specific stability data, the beyond-use date for an oral solid is capped at 180 days in tight, light-resistant containers. Terminal product types are size 3 or 4 hard gelatin or HPMC capsules administered under direct veterinary supervision, mainly to dogs for acute nonspecific diarrhoea. Felines are a recognised adverse-reaction population because opioid-induced excitation can occur at doses that are sedative in canines; capsule strength is therefore selected case-by-case by the prescribing veterinarian rather than from a uniform dosing table.

The wet-granulation route for diphenoxylate HCl veterinary tablets is selected not to improve dissolution but to prevent segregation during long campaign compression at low blend loadings. A typical granulation batch charges the API pre-blend into a high-shear mixer at a 1:10 diphenoxylate HCl-to-lactose monohydrate ratio; the granulating fluid is purified water or a povidone K30 solution added at 3–5% w/w of dry mass until the wet mass reaches a loss-on-drying range of 1.5–2.5%. The wet mass is passed through a 1.0 mm screen, dried in a fluid-bed dryer with inlet air temperature not exceeding 50°C, and milled through an 800 µm screen. The milled granules are then blended with croscarmellose sodium 2.0% w/w and magnesium stearate 0.5% w/w before compression on a rotary tablet press. The formula addition ratio at the final tablet stage is 2.5 mg diphenoxylate HCl per 250 mg tablet core, with atropine sulfate at 0.025 mg per core; the granulation intermediate is also suitable for sachet filling when a powder-for-suspension clinical unit is requested. Industry compliance for the granule and final tablet includes uniformity of mass by Ph. Eur. 2.9.5, friability by Ph. Eur. 2.9.7, and disintegration by Ph. Eur. 2.9.1, while dissolution is verified with a site-validated method under USP <711> because no public veterinary monograph for diphenoxylate tablets exists. Terminal product type is a low-dose antidiarrheal tablet, but the granule intermediate itself may be supplied as a bulk veterinary granule to licensed compounding facilities that require an already-diluted working intermediate rather than pure API. Strongly alkaline excipients such as magnesium oxide or sodium bicarbonate should be excluded from the formulation because pH values above 6 can shift the hydrochloride salt toward the free base and reduce aqueous availability in dissolution testing.

Oral liquid preparations of diphenoxylate HCl for small-animal use are formulated as either hydroalcoholic solutions or compounded aqueous suspensions, with the decision derived from the API supplier’s solubility and forced-degradation data rather than a fixed national monograph. Because the hydrochloride salt has limited aqueous solubility, the manufacturing sequence generally pre-dissolves the API in ethanol or propylene glycol before incorporation into a sorbitol- or glycerol-containing vehicle; where the reference commercial oral liquid uses 15% v/v ethanol, a veterinary compounder may reduce the alcohol fraction only when batch-specific solubility data support an alternative cosolvent system. The addition ratio is expressed per 5 mL dose: 2.5 mg diphenoxylate HCl and 0.025 mg atropine sulfate per 5 mL, with 0.1% w/v sodium benzoate as preservative in a preserved multi-dose container and pH adjusted to 3.5–4.5 using citrate buffer after reviewing the API manufacturer’s stability data. Downstream production at pharmacy or contract compounding level uses magnetic stirring for solution incorporation and high-shear homogenisation at 3,000 rpm for 5 min for suspension deagglomeration, followed by filling through calibrated peristaltic pumps with fill-volume variation controlled to ±2%. Compliance is anchored to USP <795> for non-sterile compounding and USP <51> for antimicrobial effectiveness in preserved multi-dose containers; in the absence of site-specific stability data, water-containing oral liquids are assigned a beyond-use date no longer than 14 days refrigerated. Terminal product types are amber glass oral syringes or bottles with child-resistant closures, labelled for short-term management of acute diarrhoea in dogs and cats under veterinary supervision.

Premix Homogeneity Boundaries in Veterinary Institutional Compounding

Premix intermediates are not finished dosage forms; they are controlled-dispersion powders in which diphenoxylate HCl is pre-diluted to a defined working concentration so that hospital pharmacies and compounding laboratories do not repeatedly weigh pure active pharmaceutical ingredient. A widely used premix specification sets the API mass fraction at 1.0% w/w in lactose monohydrate, produced by a double-dilution sequence of 1:10 followed by 1:10, with the final premix passed through a 500 µm screen and blended for 20 min. Homogeneity acceptance requires 10 stratified samples taken from the blender drum after discharge; relative standard deviation of peak HPLC response must not exceed 5.0%, and any sample outside 95.0–105.0% of label claim fails the lot. The premix must be stored in double polyethylene bags inside fibre drums with desiccant, and the facility environmental limit is set at 25°C and 60% RH for open handling because moisture uptake above that threshold produces clumping and variable dispensing. Compliance combines USP <795> for non-sterile compounding, 21 CFR Part 530 for veterinary extralabel use, and, for international shipments, VICH GL18 residual solvent certification and ICH Q3D elemental impurity data. Terminal product types prepared by the receiving institution include capsules, oral suspensions, and divided powders dispensed in unit-dose sachets for companion-animal treatment; the premix is not suitable for food-producing species because no Codex maximum residue limit has been allocated for diphenoxylate in meat or milk, and cross-contact with food-animal production lines must be excluded.

What Operational Limits Apply to Export API Repacking in Tropical Distribution?

Export consignments of diphenoxylate HCl veterinary-grade API are released against a tighter specification set than internal pilot batches because container headspace temperature, humidity, and multi-modal transfer can increase particle agglomeration and assay drift. The API is supplied as a white to off-white crystalline powder; loss on drying is controlled to ≤ 0.5% by Ph. Eur. 2.2.32, and the certificate of analysis must include residual solvents under VICH GL18, related substances by a stability-indicating HPLC method, and elemental impurities under ICH Q3D. Repacking is conducted in a dry area at 25°C ± 2°C and ≤ 40% RH because crystalline powders exposed to tropical dew points above 26°C can bridge in screw feeders and produce non-uniform premix ratios during customer-side dilution. The formula addition ratio at the repacking stage is not a formulation step; rather, the batch is released as 100.0% API with assay acceptance 98.0–102.0% on dried basis, and the overseas manufacturing customer performs the first dilution at 1:10 with lactose monohydrate before tablet or capsule production. Terminal product types downstream of this export-grade API are the same as those produced from domestic API: direct-compression tablets, wet-granulated tablets, veterinary compounder premixes, oral suspensions, and unit-dose capsules. The batch record must document that no food-animal line has shared transfer equipment, because diphenoxylate has no established withdrawal period in food-producing species and any contamination of milk or meat supply would trigger residue failures under importing-country veterinary drug surveillance. Published data for tropical open-container stability beyond 30 days is limited; users are instructed to requalify the API after prolonged unopened storage above 30°C with a reduced-sample HPLC assay and moisture check before accepting the lot into production.